Hospital Ruber Internacional
The cost of stem cell therapy for COPD in Spain typically ranges from $20,000 to $30,000. Prices vary depending on the clinic, the specialist’s experience, the number of stem cell infusions, and whether the cells are autologous or allogeneic. In the United States, the average price is $45,000. This means stem cell therapy for COPD in Spain can be about 44% less than in the U.S.
Spanish clinics usually include initial consultation, diagnostic tests, stem cell harvesting and processing, the infusion procedure, and follow-up visits. In the U.S., the base price often covers only the procedure itself, with extra costs for cell processing, hospital fees, and follow-up care. Always confirm what’s included in your treatment package before booking.
Why do patients choose Spain for stem cell therapy for COPD?
Access advanced Stem cell therapy for COPD solutions in trusted clinics .
| Turkey | Austria | Spain | |
| Stem cell therapy for COPD | from $12,000 | from $32,000 | from $20,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Stem cell therapy for COPD upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Stem cell therapy for COPD and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Stem cell therapy for COPD journey.
Head of Pulmonology at Teknon Medical Center with 32 years of experience of experience in COPD and clinical trials on cutting-edge therapies.
Stem cell therapy cannot cure COPD. Chronic Obstructive Pulmonary Disease involves irreversible damage to lung airways and air sacs. While mesenchymal stem cells (MSCs) show potential in reducing inflammation during investigational clinical trials, no regulatory body has approved stem cells as a definitive cure.
Bookimed Expert Insight: Spain offers a unique advantage for lung research through centers like Centro Medico Teknon. Dr. Eduardo Loeb Melus manages the EARCO European clinical registry there. This high-level data integration ensures patients access the most current, trial-based protocols rather than unverified commercial claims.
Patient Consensus: Many individuals emphasize the high out-of-pocket costs for unproven results. Most suggest sticking to evidence-based treatments while awaiting Phase 3 trial data.
Stem cell therapy does not replace conventional COPD treatments like inhalers or oxygen therapy. Medical specialists in Spain utilize mesenchymal stem cells as investigational, complementary tools. These therapies aim to reduce inflammation rather than replace standard symptom management or provide a permanent cure.
Bookimed Expert Insight: While Spain offers advanced pulmonary care at JCI-accredited centers like Hospital Ruber Internacional, patients should focus on clinical trial registries. Dr. Eduardo Loeb Melus at Centro Médico Teknon specifically coordinates trials for the Vall d'Hebron Research Institute. This indicates that the most reputable Spanish options are tied to research, not commercial clinics promising total replacement of your inhaler.
Patient Consensus: Many patients find these treatments are experimental add-ons rather than cures. You must continue your prescribed medications, as abandoning standard care can cause rapid breathing destabilization.
Stem cell therapy for COPD in Spain primarily utilizes mesenchymal stem cells (MSCs) sourced from bone marrow, adipose tissue, or umbilical cord matrix. These multipotent cells are selected for their anti-inflammatory properties and ability to support tissue healing through intravenous, nebulized, or bronchoscopy-based delivery methods.
Bookimed Expert Insight: Spain’s pulmonology infrastructure, led by experts like Dr. Eduardo Loeb Melus at Centro Médico Teknon, focuses on advanced integration. While many global clinics only offer IV delivery, leading Spanish facilities often combine systemic infusions with localized bronchoscopy to target damaged lung tissue directly.
Patient Consensus: Patients often prioritize bone-marrow-derived cells for perceived safety, though many explore umbilical cord options for convenience. Most emphasize the importance of verifying delivery methods and trial data before beginning treatment.
Patients find prominent regenerative therapy facilities in Spain primarily in Barcelona and Madrid within JCI-accredited hospitals and specialized research institutes. Key centers include Centro Médico Teknon and Hospital Ruber Internacional, which integrate advanced cellular protocols with clinical trials led by pulmonology and orthopedics specialists.
Bookimed Expert Insight: While many search for private clinics, Bookimed data shows the highest clinical safety at hospitals like Hospital Ruber Internacional, which treats 25,000 patients annually. For complex needs like COPD, choosing centers involved in European clinical registries like EARCO ensures access to validated research protocols rather than unproven commercial treatments.
Patient Consensus: Regenerative therapies for lung conditions are currently viewed as research-based rather than standard cures. Patients strongly advise consulting qualified pulmonologists at large academic centers to avoid aggressive marketing from unverified clinics.